New study tracks how long guselkumab lasts for IBD patients
NCT ID NCT07532213
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study follows 50 people with moderate to severe Crohn's disease or ulcerative colitis to see how long they stay on guselkumab in real-world settings. Researchers will measure treatment persistence and early symptom improvements using patient diaries. The goal is to understand the drug's long-term effectiveness outside of clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- guselkumab
- What this could lead to
- If successful, this could confirm guselkumab's long-term effectiveness for managing inflammatory bowel disease in everyday practice.
- What could go wrong
- This is an observational study with only 50 participants, so results may not apply broadly. It does not test new benefits or safety beyond what is already known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gastroenterologische Praxis und Crohn-Collitis Zentrum Bern
RECRUITINGBern, 3001, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a patient registry unlock the secrets of IBD?
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can we predict how kids with IBD will respond to treatment?
- Could IBD medications during pregnancy shape a Child's development?
- Can AI learn to grade endoscopy quality from video?
- Can switching IBD meds heal the gut when symptoms are quiet?